Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Respir Res · 2010 · PMC2834642 · PMID 20109213

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significancep = 0.051so close (0.05 < p ≤ 0.1)

A trend for greater time to first exacerbation was seen for moxifloxacin- vs placebo-treated patients in both the PP EOT and ITT populations, although this did not reach statistical significance (p = 0.051 and 0.062 respectively) (see Additional file 6 : Additional results, Figure S1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.